Antiplatelet medications in the secondary prevention of ischemic stroke

  • James D. Fleck
Invited Commentary
  • 33 Downloads

Conclusions

It is difficult to make general statements regarding choices in the medical management of patients with IS given its multiple mechanisms and individual patient variations. It is exceedingly important to manage all vascular risk factors in each patient, especially hypertension. Managing risk factors is as important as, or perhaps more important than, deciding on a prevention medication. Based on the previous discussion, I present my recommendations for antiplatelet secondary prevention of noncardioembolic IS.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977, 8:301–314.PubMedGoogle Scholar
  2. 2.
    The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 1978, 299:53–59.CrossRefGoogle Scholar
  3. 3.
    Hass WK, Easton JD, Adams HP Jr, et al.: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989, 321:501–507.PubMedCrossRefGoogle Scholar
  4. 4.
    Gorelick PB, Richardson D, Kelly M, et al.: Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003, 289:2947–2957.PubMedCrossRefGoogle Scholar
  5. 5.
    CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329–1339.CrossRefGoogle Scholar
  6. 6.
    Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1–13.PubMedCrossRefGoogle Scholar
  7. 7.
    Bousser MG, Eschwege E, Haguenau M, et al.: “AICLA” controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983, 14:5–14.PubMedGoogle Scholar
  8. 8.
    De Schryver EL, Algra A, van Gijn J: Cochrane review: dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 2003, 34:2072–2080.PubMedCrossRefGoogle Scholar
  9. 9.
    Mohr JP, Thompson JL, Lazar RM, et al.: A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001, 345:1444–1451.PubMedCrossRefGoogle Scholar
  10. 10.
    Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.PubMedCrossRefGoogle Scholar
  11. 11.
    Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411–2420.PubMedCrossRefGoogle Scholar
  12. 12.
    Diener HC: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet 2004, 364:331–337.PubMedCrossRefGoogle Scholar
  13. 13.
    CHARISMA: http://www.clinicaltrials.gov/ct/show/NCT00050817. Accessed August 15, 2004.Google Scholar
  14. 14.
    PRoFESS: http://www.profess-study.com. Accessed August 15, 2004.Google Scholar
  15. 15.
    SPS3: http://www.clinicaltrials.gov/ct/show/NCT00059306. Accessed August 15, 2004.Google Scholar

Copyright information

© Current Science Inc. 2005

Authors and Affiliations

  • James D. Fleck
    • 1
  1. 1.Department of NeurologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations